ValnevaValneva SE, the French specialty‑vaccine developer, has completed an €84m reserved offering, adding a useful cash buffer just as the group enters a high‑risk window for its Lyme disease and shigellosis‑vaccine candidates.
Tag Archive for: Lyme vaccine
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.